| Literature DB >> 29299136 |
Gang Ye1,2, Nan Tan3, Chenyang Meng4, Jingjie Li1, Li Jing1, Mengdan Yan1, Tianbo Jin1,5, Fulin Chen1.
Abstract
The study was aimed to explore whether the TERT and TERC polymorphisms are associated with the lung cancer risk. Five TERC and TERT polymorphisms were genotyped from 554 lung cancer patients and 603 healthy controls. We used χ2 test, genetic model, linkage disequilibrium (LD) and haplotype analyses to evaluate the association between the polymorphisms and lung cancer risk. We found that the allele "C" of rs10936599 (TERC) and the allele "T" of rs10069690 (TERT) were associated with increased risk of lung cancer (OR = 1.32, 95% CI: 1.12-1.55, P = 0.001; OR = 1.41, 95% CI: 1.14-1.76, P = 0.002, respectively). The genotype of "CC" of rs10936599, genotype "CT" of rs10069690 and genotype "GG and "AG" of rs2853677 were also associated with increased the risk of lung cancer. In addition, rs10936599 under the dominant, recessive and log-additive models; rs10069690 under the dominant, overdominant and log-additive models; rs2853677 under the dominant and log-additive models were found to be associated with increased lung cancer risk. The SNP rs2242652 was found to be associated with an increased lung cancer risk under the dominant and overdominant models without adjustment. The haplotype "TA" of TERT was also associated with an increased risk of lung cancer. Our study indicated that rs10936599 (TERC) and rs10069690, rs2242652 and rs2853677 in TERT and haplotype "TA" of TERT were revealed as risk factors of lung cancer in a Chinese Han population. However, it required to verify our result and investigate the function genetic variants and mechanism of lung cancer.Entities:
Keywords: TERC; TERT; lung cancer; single nucleotide polymorphism (SNP)
Year: 2017 PMID: 29299136 PMCID: PMC5746371 DOI: 10.18632/oncotarget.22329
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Basic characteristics of the cases and controls
| Characteristic | Case (n=554) | Control (n=603) | ||
|---|---|---|---|---|
| Gender | Male | 416 | 469 | 1.16a |
| Female | 138 | 134 | ||
| Age (year; mean ± SD) | 58.18±10.534 | 48.24±13.053 |
SD: Standard deviation
aP value was calculated by Welch's t test;
bP value was calculated by Pearson's χ 2 test.
Association between the SNPs of TERC and TERT and the risk of lung cancer
| SNP ID | Position | Band | Alleles A/B | Gene(s) | MAF | HWE- | OR (95 % CI) | ||
|---|---|---|---|---|---|---|---|---|---|
| Case | Control | ||||||||
| rs10936599 | 169492101 | 3q26.2 | C/T | 0.493 | 0.425 | 0.6169 | 1.32 (1.12-1.55) | ||
| rs10069690 | 1279790 | 5p15.33 | T/C | 0.196 | 0.147 | 0.1899 | 1.41 (1.14-1.76) | ||
| rs2242652 | 1280028 | 5p15.33 | A/G | 0.190 | 0.163 | 0.5489 | 1.21 (0.98-1.50) | 0.079 | |
| rs2853677 | 1287194 | 5p15.33 | G/A | 0.403 | 0.366 | 0.7929 | 1.17 (1.00-1.39) | 0.060 | |
| rs2853676 | 1288547 | 5p15.33 | T/C | 0.175 | 0.154 | 0.7565 | 1.16 (0.93-1.45) | 0.184 | |
SNP: single nucleotide polymorphism; MAF: Minor allele frequency; HWE: Hardy–Weinberg equilibrium; OR: Odds ratio; 95 % CI: 95 % Confidence interval
P values were calculated using two-sided Chi-squared test.
P < 0.05 indicates statistical significance.
Genetic model analyses of the association between the SNPs and lung cancer risk
| SNP-ID | Model | Genotype | Case (%) | Control (%) | Without adjustment | With adjustment | ||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||||||
| rs10936599 | Codominant | T/T | 151 (27.4%) | 203 (33.7%) | 1 | 1 | ||
| C/T | 258 (46.7%) | 288 (47.8%) | 1.20 (0.92-1.58) | 1.22 (0.91-1.64) | ||||
| C/C | 143 (25.9%) | 112 (18.6%) | 1.72 (1.24-2.38) | 1.72 (1.21-2.45) | ||||
| Dominant | T/T | 151 (27.4%) | 203 (33.7%) | 1 | 1 | |||
| C/T-C/C | 401 (72.6%) | 400 (66.3%) | 1.35 (1.05-1.73) | 1.36 (1.04-1.79) | ||||
| Recessive | T/T-C/T | 409 (74.1%) | 491 (81.4%) | 1 | 1 | |||
| C/C | 143 (25.9%) | 112 (18.6%) | 1.53 (1.16-2.03) | 1.52 (1.12-2.06) | ||||
| Overdominant | T/T-C/C | 294 (53.3%) | 315 (52.2%) | 1 | 0.730 | 1 | 0.850 | |
| C/T | 258 (46.7%) | 288 (47.8%) | 0.96 (0.76-1.21) | 0.98 (0.76-1.25) | ||||
| Log-additive | --- | --- | --- | 1.30 (1.11-1.53) | 1.30 (1.09-1.55) | |||
| rs10069690 | Codominant | C/C | 354 (64%) | 436 (73.4%) | 1 | 1 | ||
| C/T | 181 (32.7%) | 141 (23.7%) | 1.58 (1.22-2.05) | 1.62 (1.22-2.15) | ||||
| T/T | 18 (3.2%) | 17 (2.9%) | 1.30 (0.66-2.57) | 1.38 (0.66-2.88) | ||||
| Dominant | C/C | 354 (64%) | 436 (73.4%) | 1 | 1 | |||
| C/T-T/T | 199 (36%) | 158 (26.6%) | 1.55 (1.21-1.99) | 1.59 (1.21-2.09) | ||||
| Recessive | C/C-C/T | 535 (96.8%) | 577 (97.1%) | 1 | 0.700 | 1 | 0.630 | |
| T/T | 18 (3.2%) | 17 (2.9%) | 1.14 (0.58-2.24) | 1.20 (0.58-2.50) | ||||
| Overdominant | C/C-T/T | 372 (67.3%) | 453 (76.3%) | 1 | 1 | |||
| C/T | 181 (32.7%) | 141 (23.7%) | 1.56 (1.21-2.03) | 1.59 (1.20-2.11) | ||||
| Log-additive | --- | --- | --- | 1.41 (1.13-1.76) | 1.45 (1.14-1.83) | |||
| rs2242652 | Codominant | G/G | 358 (64.9%) | 425 (70.5%) | 1 | 0.100 | 1 | 0.150 |
| G/A | 178 (32.2%) | 160 (26.5%) | 1.32 (1.02-1.71) | 1.32 (1.00-1.74) | ||||
| A/A | 16 (2.9%) | 18 (3%) | 1.06 (0.53-2.10) | 1.06 (0.50-2.23) | ||||
| Dominant | G/G | 358 (64.9%) | 425 (70.5%) | 1 | 1 | 0.061 | ||
| G/A-A/A | 194 (35.1%) | 178 (29.5%) | 1.29 (1.01-1.66) | 1.29 (0.99-1.69) | ||||
| Recessive | G/G-G/A | 536 (97.1%) | 585 (97%) | 1 | 0.930 | 1 | 0.940 | |
| A/A | 16 (2.9%) | 18 (3%) | 0.97 (0.49-1.92) | 0.97 (0.46-2.04) | ||||
| Overdominant | G/G-A/A | 374 (67.8%) | 443 (73.5%) | 1 | 1 | 0.051 | ||
| G/A | 178 (32.2%) | 160 (26.5%) | 1.32 (1.02-1.70) | 1.32 (1.00-1.73) | ||||
| Log-additive | --- | --- | --- | 1.21 (0.98-1.51) | 0.079 | 1.21 (0.96-1.53) | 0.110 | |
| rs2853677 | Codominant | A/A | 191 (34.5%) | 244 (40.5%) | 1 | 0.110 | 1 | |
| A/G | 279 (50.4%) | 277 (45.9%) | 1.29 (1.00-1.66) | 1.32 (1.00-1.73) | ||||
| G/G | 84 (15.2%) | 82 (13.6%) | 1.31 (0.91-1.87) | 1.60 (1.08-2.37) | ||||
| Dominant | A/A | 191 (34.5%) | 244 (40.5%) | 1 | 0.036 | 1 | ||
| A/G-G/G | 363 (65.5%) | 359 (59.5%) | 1.29 (1.02-1.64) | 1.38 (1.06-1.79) | ||||
| Recessive | A/A-A/G | 470 (84.8%) | 521 (86.4%) | 1 | 0.450 | 1 | 0.082 | |
| G/G | 84 (15.2%) | 82 (13.6%) | 1.14 (0.82-1.58) | 1.37 (0.96-1.97) | ||||
| Overdominant | A/A-G/G | 275 (49.6%) | 326 (54.1%) | 1 | 0.130 | 1 | 0.250 | |
| A/G | 279 (50.4%) | 277 (45.9%) | 1.19 (0.95-1.50) | 1.16 (0.90-1.49) | ||||
| Log-additive | --- | --- | --- | 1.18 (0.99-1.39) | 0.060 | 1.28 (1.06-1.54) | ||
| rs2853676 | Codominant | C/C | 380 (68.6%) | 429 (71.3%) | 1 | 0.270 | 1 | 0.150 |
| C/T | 154 (27.8%) | 160 (26.6%) | 1.09 (0.84-1.41) | 1.14 (0.86-1.52) | ||||
| T/T | 20 (3.6%) | 13 (2.2%) | 1.74 (0.85-3.54) | 2.01 (0.93-4.31) | ||||
| Dominant | C/C | 380 (68.6%) | 429 (71.3%) | 1 | 0.320 | 1 | 0.180 | |
| C/T-T/T | 174 (31.4%) | 173 (28.7%) | 1.14 (0.88-1.46) | 1.21 (0.92-1.59) | ||||
| Recessive | C/C-C/T | 534 (96.4%) | 589 (97.8%) | 1 | 0.140 | 1 | 0.085 | |
| T/T | 20 (3.6%) | 13 (2.2%) | 1.70 (0.84-3.44) | 1.93 (0.90-4.13) | ||||
| Overdominant | C/C-T/T | 400 (72.2%) | 442 (73.4%) | 1 | 0.640 | 1 | 0.460 | |
| C/T | 154 (27.8%) | 160 (26.6%) | 1.06 (0.82-1.38) | 1.11 (0.84-1.47) | ||||
| Log-additive | --- | --- | --- | 1.16 (0.93-1.44) | 0.180 | 1.23 (0.97-1.56) | 0.085 | |
SNP: single nucleotide polymorphism; OR: Odds ratio; 95% CI: 95% Confidence interval
P < 0.05 indicates statistical significance.
Figure 1Haplotype block map for SNPs of the TERT gene
LD is displayed by standard color schemes with bright red for very strong LD (LOD > 2, D’ = 1), pink red (LOD > 2, D’< 1) and blue (LOD < 2, D’= 1) for partial linkage, and white (LOD < 2, D’< 1) for complete recombination.
Haplotype frequency and their association with lung cancer risk
| SNPs | Haplotype | Freq% | OR (95%CI) | |||
|---|---|---|---|---|---|---|
| case | control | |||||
| rs10069690|rs2242652 | CG | 0.800 | 0.832 | - | 1 | - |
| TA | 0.187 | 0.146 | 1.32 (1.06 - 1.65) | |||
OR: Odds ratio; 95% CI: 95% Confidence interval
aP value was calculated by logistic regression crude analysis.
bP value was calculated by logistic regression analysis adjusted by gender and age.
P < 0.05 indicates statistical significance.
The sequences of primers for SNPs
| SNP-ID | 2nd-PCRP | 1st-PCRP | UEP-SEQ |
|---|---|---|---|
| rs10936599 | ACGTTGGATGCAAGGGTAAAATTCCATTCTG | ACGTTGGATGTTCCCGCTGTTTGTTCAGTC | ATGCAGTATTCGCACCA |
| rs10069690 | ACGTTGGATGATGTGTGTTGCACACGGGAT | ACGTTGGATGCCTGTGGCTGCGGTGGCTG | GGGATCCTCATGCCA |
| rs2242652 | ACGTTGGATGAGGCTCTGAGGACCACAAGA | ACGTTGGATGACAGCAGGACACGGATCCAG | gtcgGAGGACCACAAGAAGCAGC |
| rs2853677 | ACGTTGGATGGCAAGTGGAGAATCAGAGTG | ACGTTGGATGATCCAGTCTGACAGTCGTTG | gggtAATCAGAGTGCACCAG |
| rs2853676 | ACGTTGGATGCAAAACTAAGACCCAAGAGG | ACGTTGGATGTGTCTCCTGCTCTGAGACC | agatGGAAGTCTGACGAAGGC |
SNP: Single nucleotide polymorphism; PCRP: Polymerase chain reaction primer; UEP: unique base extension primer; SEQ: Single base extension reaction
Sequences are written in the 5’→3’ (left to right) orientation.